Cargando…

Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases

Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Savelli, Giordano, Muni, Alfredo, Barbieri, Roberto, Valmadre, Giuseppe, Biasiotto, Giorgio, Minari, Chiara, Ghimenton, Claudio, Pagani, Renato, Pecini, Elisa, Falcone, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649877/
https://www.ncbi.nlm.nih.gov/pubmed/29147381
http://dx.doi.org/10.14740/wjon739w
Descripción
Sumario:Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which (68)Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy.